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Abstract
In hemodialysis patients, a native arteriovenous fistula (AVF) is the preferred form of permanent vascular access. Despite
recent improvements, vascular access dysfunction remains an important cause of morbidity in these patients. In this
prospective observational cohort study, we evaluated potential risk factors for native AVF dysfunction. We included 68
patients with chronic renal disease stage 5 eligible for AVF construction at the Department of General and Vascular Surgery,
Central Clinical Hospital Ministry of Internal Affairs, Warsaw, Poland. Patient characteristics and biochemical parameters
associated with increased risk for AVF failure were identified using Cox proportional hazards models. Vessel biopsies were
analyzed for inflammatory cells and potential associations with biochemical parameters. In multivariable analysis,
independent predictors of AVF dysfunction were the number of white blood cells (hazard ratio [HR] 1.67; 95% confidence
interval [CI] 1.24 to 2.25; p,0.001), monocyte number (HR 0.02; 95% CI 0.00 to 0.21; p=0.001), and red blood cell
distribution width (RDW) (HR 1.44; 95% CI 1.17 to 1.78; p,0.001). RDW was the only significant factor in receiver operating
characteristic curve analysis (area under the curve 0.644; CI 0.51 to 0.76; p=0.046). RDW.16.2% was associated with a
significantly reduced AVF patency frequency 24 months after surgery. Immunohistochemical analysis revealed CD45-
positive cells in the artery/vein of 39% of patients and CD68-positive cells in 37%. Patients with CD68-positive cells in the
vessels had significantly higher white blood cell count. We conclude that RDW, a readily available laboratory value, is a novel
prognostic marker for AVF failure. Further studies are warranted to establish the mechanistic link between high RDW and
AVF failure.
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Introduction
In hemodialysis patients, a native arteriovenous fistula (AVF) is
the preferred form of permanent vascular access [1]. Complica-
tions associated with vascular access for hemodialysis are
important causes of morbidity among end-stage renal disease
patients [2]. In 2% to 53% of patients, AVFs are never usable for
dialysis (primary failures), owing to early thrombosis or failure to
mature [3]. The major cause of late AVF failure is venous stenosis
and subsequent thrombosis due to progressive neointimal hyper-
plasia [4]. The thrombosis-free patency rate in patients with an
autogenous AVF is 42% to 90% at 12 months [3,5].
Risk factors for AVF thrombosis include diabetes mellitus,
anticardiolipin antibodies, patient age, previous use of a dialysis
catheter, hypoalbuminemia, and high serum levels of lipoprotein
A and fibronectin. Patients with diabetes mellitus have elevated
serum coagulation factors and impaired fibrinolysis due to elevated
concentrations of plasminogen activator inhibitor-1 (PAI-1),
resulting in a higher frequency of atherothrombotic events as well
as venous thrombosis [6–8]. High anti-Cytomegalovirus IgG levels
have also been identified as an independent risk factor for AVF
thrombosis [9,10] but we were unable to confirm these findings
[11].
Patients with end-stage renal disease have a bleeding diathesis
caused by a reduced number of platelets and alterations in platelet
adhesion and aggregation. Paradoxically, these patients are also
predisposed to thrombosis due to impaired endothelial function
and elevations in PAI-1, homocysteine, and von Willebrand factor
[12]. Prothrombotic alternations in coagulation factors, such as
increases in fibrinogen, thromboplastin, and fibrinopeptide A
levels and in the activity of factors VII, VIII, and IX-XII, have
also been demonstrated in patients with renal failure [12].
Persistent inflammation has also been identified as a risk for
AVF thrombosis. Serum C reactive protein (CRP) levels greater
than 0.8 mg/dl conferred an 16.6 times increased risk for vascular
access thrombosis in patients with native AVF [13]. Elevations in
other inflammatory factors such as IL-6 and PAI-1 have also been
associated with AVF failure [14].
Although numerous risk factors and correlates to AVF
dysfunction have been identified, they do not explain all cases of
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36482vascular access thrombosis. In this prospective cohort study, we
evaluated the predictive value of numerous biochemical factors,
assessed at the time of surgery, for AVF failure.
Materials and Methods
Ethics statement
The study was approved by the Ethical Committee of the
Central Clinical Hospital Ministry of Internal Affairs (40/2005)
and the Ethical Committee at Karolinska Institutet (2011/411-31/
1). Written informed consent was obtained from all patients.
Study design and patients
Patients with stage 5 chronic kidney disease who had an
expected survival time .12 months and qualified for primary
AVF construction were included in the study. The exclusion
criteria were previous surgery of the forearm, advanced heart
failure (New York Heart Association class III or IV), or obstruction
of the cephalic vein or radial artery before surgery. Between June
1, 2006, and September 30, 2007, 68 patients with established
chronic kidney disease received a primary AVF between the radial
artery and cephalic vein at the Department of General and
Vascular Surgery Central Clinical Hospital Ministry of Internal
Affairs and were included in the study. The patients were followed
for 24 months after surgery. The primary outcome measure was
AVF failure.
At 12 and 52 weeks after surgery and in cases of dysfunction,
AVF patency was evaluated by ultrasonography to measure fistula
blood flow and cephalic vein diameter and to identify arterial or
venous stenosis. AVFs with signs of pathology were evaluated with
angiography before AVF failure was diagnosed. AVF dysfunction
was defined as failure of the AVF to mature or thrombosis or
stenosis that decreased blood flow and resulted in inadequate
dialysis.
Analysis of blood and biochemical factors
Blood samples were taken at the day of surgery and evaluated
for the factors shown in Tables 1 and 2 using routine methods at
the Central Clinical Hospital of Ministry of Internal Affairs. Blood
parameters were analyzed with an automated hematology
analyzer (Sysmex XT 2000, GMI Inc.). Biochemical factors were
analyzed with a Cobas Integra 800 system (Roche); hemostasis
factors were analyzed with a BCS XP System (Siemens). Albumin-
corrected calcium was calculated as total serum calcium (mg/
dL)+0.07046(34 – serum albumin (g/L)).
Cytokine analysis
Patient serum was analyzed for IL-12p70, IFN-c, IL-17A, IL-2,
MCP-1, IL-10, IL-8, IL-6, IFN-a, IL-1b and TNF-a using the
bead based FlowCytomix Multiplex Kit (Bender MedSystems,
Vienna, Austria) in accordance with the manufacturer’s instruc-
tions.
Immunohistochemistry
During surgery, 5-mm segments of the radial artery and
cephalic vein were harvested for histological evaluation. The
biopsies were fixed in formalin and embedded in paraffin. Sections
(4 mm thick) were cut, deparaffinized in xylene (VWR Interna-
tional, Radnow, PA), and hydrated in a descending alcohol series.
After sequential incubation with 3% hydrogen peroxide (Merck,
Darmstadt, Germany) for 15 minutes at room temperature to
block endogenous peroxidase, with avidin and biotin (DakoCyto-
mation, Glostrop, Denmark) for 20 minutes at room temperature,
and with Fc-receptor blocker for 30 minutes (Innovex Biosciences,
Richmond, CA), the slides were incubated with primary antibodies
against CD68 (IgG3, clone: PG-M1), CD45 (IgG1, clone:
2B11+PD7/26), and CD31 (All from DakoCytomation, Glostrop,
Denmark) overnight at 4uC. Positive cells were detected with the
Supersensitive Link Label Detection System (BioGenex, San
Ramon CA). Briefly, slides were incubated with biotinylated goat
anti-mouse antibodies and then with horseradish peroxidase–
labeled streptavidin. Antigens were visualized with diaminobenzi-
dine (Innovex Biosciences, Richmond, CA). The slides were
counterstained with hematoxylin (Vector Laboratories, Burlin-
game, CA) before mounting. Positive cells and all cells in the
biopsies were counted. The percentage of positive cells or grading
as positive or negative was used in the subsequent analysis.
Statistical analysis
Differences in categorical factors were determined with the chi-
square test; differences in continuous factors were determined by
one-way analysis of variance. Differences in continuous values
between two groups were assessed with the t test or Mann-Whitney
U test.
For univariable analysis of all factors, Cox proportional hazards
models were used. All factors that met the significance criterion
(p,0.2) were considered for inclusion in the final model; to avoid
multicollinearity, these factors were analyzed with Pearson’s
correlation coefficient. For variables with a correlation coefficient
.0.8, only one of the variables was kept in the final model; this
decision was based on medical judgment. Due to the small sample
size only biochemical factors were considered for inclusion in the
final model, thus medication with calcium antagonists (p=0.06)
was excluded. Receiver operating characteristic (ROC) curves
were used to establish a cutoff point between high and low value
for all the significant factors in multivariable analysis. Survival
curves were calculated for the various groups using the Kaplan-
Meier method and compared by the log-rank test. All values are
reported as mean 6 standard deviation (SD) or percentages; 95%
confidence intervals (CIs) are provided where appropriate.
MedCalc version 12.2.1 and GraphPad Prism version 4.0c
software were used for all analyses and graphs.
Results
Inflammatory markers are significantly higher in patients
with early AVF dysfunction
Of the 68 patients in the study, 11 (16%) had early AVF
dysfunction (defined as failure to mature or thrombosis within 2
months) and 23 (34%) patients had late dysfunction (3–24 months).
The average time to dysfunction was 766 months. The AVF
failure rate at 24 months was 50%; 13% were due to primary
failure, consistent with previous observations [5,15]. In the patient
population with AVF survival .24 months, 6 (18%) patients had
coronary disease, stroke or transient ischemic attack. Similar
incident rates, 2 patients (18%), were observed in the early AVF
dysfunction group. These incidents were although more prevalent
in the late AVF dysfunction patient population where 15 (65%)
patients were affected.
The demographic, biochemical, and clinical characteristics of
the patients are shown in Table 1 and Table S1. Patients with
early AVF dysfunction had higher C-reactive protein (CRP) levels
than patients with late dysfunction or no dysfunction (18.6616.8
versus 8.667.7 and 7.366.6, respectively; p=0.01), a higher white
blood cell count (WBC) (9.362.3 versus 7.261.9 and 7.161.7,
p=0.01), red blood cell distribution width (RDW) (16.962.4
versus 15.662.3 and 14.861.7, p=0.03), and a higher platelet
count (3296143 versus 231680 and 257689, p=0.049). There
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S1). Patients with early or late AVF dysfunction had a lower red
blood cell count (RBC) (3.260.3 and 3.560.4 versus
3.760.6610
12/L, p=0.048) and lower levels of serum albumin
(3.261.1 and 3.660.6 versus 4.060.4 g/dL, p=0.003). There
were no differences in patient characteristics, medications, or the
remaining biochemical parameters analyzed. No differences in the
serum levels of IL-12p70, IFN-c, IL-17A, IL-2, MCP-1, IL-10, IL-
8, IL-6, IFN-a, IL-1b and TNF-a were found (Table S2).
Table 1. Patient Characteristics.
Patient characteristics
Early AVF
dysfunction
(n=11)
Late AVF
dysfunction
(n=23)
No AVF
dysfunction
(n=34) p
All patients
(n=68)
Mean age (years, 6SD) 68612 60615 61616 0.33 62615
Gender [n (%)] 0.87
Male 7 (63.6) 15 (65.2) 24 (70.6) 46 (67.6)
Female 4 (36.4) 8 (34.8) 10 (29.4) 22 (32.4)
Smoker [n (%)] 4 (36.4) 13 (56.5) 16 (47.1) 0.53 33 (48.5)
Other diseases [n (%)]
Heart failure 7 (70.0) 18 (81.8) 28 (84.8) 0.45 53 (81.5)
Diabetes 2 (22.2) 12 (54.5) 8 (25.8) 0.07 22 (35.5)
Hyperlipidemia 3 (33.3) 3 (13.6) 8 (25.8) 0.41 14 (22.6)
Hypertension 7 (70.0) 18 (81.8) 28 (84.8) 0.57 53 (81.5)
Medications [n (%)]
Antithrombotic agents 2 (20.0) 8 (34.8) 12 (40.0) 0.52 22 (34.9)
Anticoagulative agents 1 (11.1) 0 (0.0) 1 (3.3) 0.28 2 (3.2)
b blockers 4 (40.0) 18 (78.3) 23 (74.2) 0.07 45 (70.3)
Calcium antagonists 4 (40.0) 15 (65.2) 24 (77.4) 0.09 43 (67.2)
ACEI 3 (30.0) 11 (47.8) 14 (45.2) 0.62 28 (43.8)
Statins 2 (22.2) 9 (39.1) 15 (48.4) 0.36 26 (41.3)
Biochemical parameters
C-reactive protein (mg/L, 6 SD) 18.6616.8 8.667.7 7.366.6 0.01 9.269.3
Procalcitonin (ng/L, 6 SD) 0.2460.08 0.1960.07 0.2160.06 0.24 0.2160.07
HDL cholesterol (mg/dL, 6 SD) 52.1618.5 50.8618.0 56.7617.6 0.54 54.2617.7
LDL cholesterol (mg/dL, 6 SD) 108.6648.1 104.5653.1 99.5645.7 0.89 102.4647.7
Triglyceride (mg/dL, 6 SD) 158.4675.8 152.4697.1 148.6682.4 0.96 151.1685.2
Creatinine (mg/dL, 6 SD) 5.261.9 4.661.4 5.161.9 0.74 5.161.8
Albumin (g/dL, 6 SD) 3.261.1 3.660.6 4.060.4 0.003 3.860.7
Albumin corrected calcium (mg/L, 6 SD) 8.760.6 8.260.7 8.660.4 0.09 8.560.6
White blood cell count (10
9 cells/L, 6 SD) 9.362.3 7.261.9 7.161.7 0.01 7.462.0
Neutrophils (10
9 cells/L, 6 SD) 6.262.6 4.861.6 4.661.2 0.06 4.961.6
Lymphocytes (10
9 cells/L, 6 SD) 1.660.3 1.860.8 1.660.7 0.41 1.760.7
Monocytes (10
9 cells/L, 6 SD) 0.760.2 0.660.2 0.760.3 0.22 0.760.3
Hematocrit (%, 6 SD) 28.763.0 30.863.6 32.364.5 0.07 31.364.1
Red blood cells (610
12/L, 6 SD) 3.260.3 3.560.4 3.760.6 0.048 3.560.5
Hemoglobin (g/dL, 6 SD) 9.761.0 10.461.4 10.961.5 0.08 10.661.5
MCV (fL, 6 SD) 89.462.6 89.367.7 89.164.7 0.99 89.265.8
MCH (pg, 6 SD) 30.161.4 30.263.1 30.462.0 0.93 30.362.4
RDW (%, 6 SD) 16.962.4 15.662.3 14.861.7 0.03 15.462.1
Platelets (610
3/mL, 6 SD) 3296143 231680 257689 0.049 257698
Iron (mmol/L, 6 SD) 10.963.9 11.565.7 11.566.9 0.96 11.466.1
Transferrin (g/L, 6 SD) 1.860.3 1.960.5 1.860.5 0.77 1.860.4
Ferritin (mg/L, 6 SD) 170.46104.7 189.36202.6 235.76314.5 0.69 209.46254.1
Boldface indicates statistically significant values (p,0.05). ACEI, angiotensin-converting enzyme inhibitor; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; RDW, red blood cell distribution width.
doi:10.1371/journal.pone.0036482.t001
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risk factors for AVF failure
The individual predictive values of all parameters were assessed
by univariable analysis using Cox regression models (Table 2;
results from parameters in Table S1 are not shown but all were
p.0.2). Increases in CRP (HR 1.04; 95% CI 1.00 to 1.08;
p=0.040), WBC (1.22; 95% CI 1.00 to 1.49; p=0.048), or RDW
(HR 1.18; 95% CI 1.02 to 1.37; p=0.029) significantly increased
the risk of AVF dysfunction. The risk of AVF dysfunction was
reduced by increases in serum albumin (HR 0.43; 95% CI 0.26 to
0.71; p=0.001), calcium (HR 0.05; 95% CI 0.01 to 0.28;
p=0.001) and RBC (HR 0.46; 95% CI 0.22 to 0.96; p=0.040).
Of note, no significant predictive effects of calcium were retained
after adjustment for albumin (HR 0.60; 95% CI 0.30 to 1.19;
p=0.145).
For the multivariable analyses, all potentially significant
biochemical variables (p,0.2) in the univariable analyses were
included. Hematocrit and hemoglobin were excluded from the
Table 2. Results of Univariable and Multivariable Analyses.
Patient characteristics
Univariable analysis HR
(95% CI) p Multivariable analysis p
Age (y) 1.01 (0.98 to 1.03) 0.517
Male 0.90 (0.45 to 1.82) 0.780
Smoking 1.03 (0.53 to 2.01) 0.934
Other diseases
Heart failure 1.46 (0.74 to 2.88) 0.280
Diabetes 1.58 (0.78 to 3.19) 0.207
Hyperlipidemia 0.85 (0.35 to 2.06) 0.716
Hypertension 0.65 (0.28 to 1.51) 0.323
Medications
Antithrombotic agents 0.74 (0.35 to 1.56) 0.433
Anticoagulative agents 1.23 (0.17 to 8.95) 0.838
b blockers 0.68 (0.33 to 1.40) 0.300
Calcium antagonists 0.52 (0.26 to 1.03) 0.061
ACEI 0.88 (0.44 to 1.75) 0.722
Statins 0.67 (0.32 to 1.38) 0.278
Biochemical parameters
C-reactive protein (mg/L, 6 SD) 1.04 (1.00 to 1.08) 0.040 1.00 (0.95 to 1.05) 0.895
Procalcitonin (ng/L, 6 SD) 0.23 (0.00 to 65.00) 0.609
HDL cholesterol (mg/dL, 6 SD) 0.99 (0.96 to 1.01) 0.367
LDL cholesterol (mg/dL, 6 SD) 1.00 (0.99 to 1.01) 0.637
Triglyceride (mg/dL, 6 SD) 1.00 (1.00 to 1.01) 0.893
Creatinine (mg/dL, 6 SD) 0.99 (0.81 to 1.21) 0.913
Albumin (g/dL, 6 SD) 0.43 (0.26 to 0.71) 0.001 0.61 (0.32 to 1.16) 0.137
Albumin corrected calcium (mg/L, 6 SD) 0.60 (0.30 to 1.19) 0.145 0.50 (0.22 to 1.12) 0.094
White blood cell count (10
9 cells/L, 6 SD) 1.22 (1.00 to 1.49) 0.048 1.67 (1.24 to 2.25) ,0.001
Neutrophils (10
9 cells/L 6 SD) 1.31 (0.99 to 1.72) 0.056
Lymphocytes (10
9 cells/L 6 SD) 1.17 (0.71 to 1.93) 0.553
Monocytes (10
9 cells/L 6 SD) 0.31 (0.07 to 1.43) 0.040 0.02 (0.00 to 0.21) 0.001
Hematocrit (%, 6 SD) 0.92 (0.84 to 1.00) 0.062
Red blood cells (610
12/L, 6 SD) 0.46 (0.22 to 0.96) 0.040 0.98 (0.25 to 3.89) 0.973
Hemoglobin (g/dL, 6 SD) 0.79 (0.61 to 1.01) 0.066
MCV (fL, 6 SD) 1.01 (0.94 to 1.07) 0.866
MCH (pg, 6 SD) 0.96 (0.83 to 1.12) 0.645
RDW (%, 6 SD) 1.18 (1.02 to 1.37) 0.029 1.44 (1.17 to 1.78) ,0.001
Platelets (610
3/mL, 6 SD) 1.00 (1.00 to 1.00) 0.843
Iron (mmol/L, 6 SD) 0.99 (0.94 to 1.05) 0.849
Transferrin (g/L, 6 SD) 1.03 (0.48 to 2.19) 0.947
Ferritin (mg/L, 6 SD) 1.00 (1.00 to 1.00) 0.516
Boldface indicates statistically significant values (p,0.05). ACEI, angiotensin-converting enzyme inhibitor; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; RDW, red blood cell distribution width.
doi:10.1371/journal.pone.0036482.t002
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2=0.86
and r
2=0.82, respectively; both p,0.001). Neutrophil count was
excluded because it correlated strongly with WBC (r
2=0.81;
p,0.001). The WBC (HR 1.67; 95% CI 1.24 to 2.25; p,0.001),
number of monocytes (HR 0.02; 95% CI 0.00 to 0.21; p=0.001),
and RDW (HR 1.44; 95% CI 1.17 to 1.78; p,0.001) were
significant independent predictors of AVF function after adjust-
ment for RBC, albumin, albumin-corrected calcium and CRP. To
exclude the possibility that the risk increase reflected by RDW was
confounded by anemia, we analyzed additional models in which
RBC was replaced with hemoglobin or hematocrit. The WBC,
monocyte numbers, and RDW remained significant independent
predictors of AVF function in these models (data not shown).
Receiver operating characteristic (ROC) curve analysis was
performed for WBC, monocyte count and RDW to determine
appropriate cutoff values. Significant differences in the distribution
were only found for RDW (area under the curve 0.644; CI 0.51 to
0.76; p=0.046) (Figure 1A). On the basis of ROC curve analysis
the upper quartile of RDW values (.16.2% versus #16.2%) was
found to be the best cutoff value for predicting AVF failure. In the
patients with RDW values in the highest quartile, Kaplan-Meier
plots demonstrated an increased frequency of AVF failure
(p=0.036, log-rank test) (Figure 1B). At the end of the observation
period, the percentage of patients with a functioning AVF was
much lower in patients with RDW values in the highest quartile
than in patients with RDW values in the three lower quartiles
combined (21% versus 59%, and 30% versus 61% if primary
failures are excluded).
The WBC and RDW correlated negatively with albumin
(r
2=20.29, p=0.039 and r
2=20.31, p=0.025, respectively).
RDW correlated positively with CRP (r
2=0.30; p=0.028) but
showed no correlation with hematocrit, hemoglobin, or RBC.
Monocyte numbers, which also independently predicted AVF
dysfunction, correlated positively with RBC (r
2=0.34, p=0.010),
hematocrit (r
2=0.31, p=0.019), and hemoglobin (r
2=0.28,
p=0.031). Although statistically significant, all theses correlations
were weak.
Inflammatory cells are frequently found in the cephalic
vein and radial artery
Inflammatory cells in the cephalic vein are found in 25% of
patients at the time of AVF construction [16], and are frequently
found in failed AVFs [17]. Since RDW may reflect an
inflammatory state that potentially could reflect the increased risk
associated with high RDW, we evaluated the radial artery and
cephalic vein biopsies for inflammatory cells. CD68-positive cells
(monocytes/macrophages) were found in 37% of the patients, and
leukocytes (CD45-positive cells) were found in 39% of the patients;
both types of cells were located predominantly in the arterial and
venous intima and media (Figure 2). No significant differences in
the number of CD68- or CD45-positive cells in the arteries or
veins were observed between the three patient subpopulations
divided according to AVF patency time (data not shown). The
patients in whom CD68-positive cells were found in the vessel
biopsies had significantly higher WBCs (p=0.002) (Figure 3B) but
no significant differences in RDW or monocyte numbers (Figure 3).
No significant differences in WBC, RDW, or monocyte numbers
were found in patients whose arteries/veins were infiltrated by
CD45-positive cells (Figure 3).
Discussion
AVF dysfunction remains a major cause of morbidity in
hemodialysis patients and leads to significant health care costs.
This prospective study showed that WBC, monocyte count, and
RDW are significant independent predictors of AVF dysfunction.
Importantly, the magnitude of the increased risk for AVF failure
associated with increases in WBC and RDW was clinically
relevant. A one-unit increase in WBC or RDW increased the risk
of AVF failure by 67% and 44%, respectively, and RDW.16.2%
was associated with a significantly reduced AVF patency rate 24
months after surgery.
RDW is a measurement of anisocytosis and was initially
constructed to aid in the evaluation of anemia. It is calculated as
the standard deviation of the red blood cell volume divided by the
Figure 1. RDW is a predictor of AVF patency. Receiver operating
characteristic curve analysis for RDW showed an area under the curve of
0.644 (CI 0.51 to 0.76; p=0.046) (A). RDW values in the highest quartile
(.16.2%) were associated with a significantly reduced AVF patency rate
at 24 months after surgery (p=0.036). The Kaplan-Meier curves were
compared with the log-rank test (B).
doi:10.1371/journal.pone.0036482.g001
Figure 2. Inflammatory cells are present in the arterial and
venous vessel wall. Leukocytes, defined as CD45-positive cells, were
found in the radial artery or cephalic vein or both in 39% of the
patients. Monocytes/macrophages, defined as CD68-positive cells, were
found in the vessel wall in 37% of the patients. Both cell types were
most frequently located in the arterial and venous intima and media.
The larger squares are magnifications of the smaller ones.
doi:10.1371/journal.pone.0036482.g002
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laboratory blood count equipment [18]. RDW has emerged as a
strong independent predictive factor for mortality in patients with
chronic and acute heart failure [19–21], acute coronary
syndromes [22], and pulmonary hypertension [23]. Furthermore,
in a large study, RDW was related to the risk of death and
cardiovascular events in patients without symptomatic heart
failure who had suffered a myocardial infarction [24]. The
usefulness of RDW as a predictor of thromboembolic conditions
has been sparsely evaluated; however, patients with an elevated
RDW are more likely to have had a stroke (OR 1.71; 95% CI
1.20–2.45) [25]. RDW is readily available and affordable, which
increases its value as a prognostic marker.
The mechanisms by which elevation in RDW contributes to an
increase in mortality risk and the risk for cardiovascular events are
unknown. It has been suggested that RDW reflects ineffective red
blood cell production, inflammation, impaired renal function, and
malnutrition [20]. Indeed, RDW is increased in patients with iron,
folate, or vitamin B12 deficiency [18]. The risk for AVF failure
associated with increasing RDW is likely not due to anemia, as
neither hematocrit, hemoglobin, iron, transferrin nor ferritin levels
affected AVF failure risk in univariable analysis or correlated with
RDW. In the multivariable analysis, RDW remained a significant
risk factor after adjustment for RBC/hematocrit/hemoglobin and
other factors, making it unlikely that our findings were confounded
by anemia. Information on folate or vitamin B12 deficiencies in our
patients were not available. No risk was associated with mean
corpuscular volume (MCV), which is affected in these deficiencies
(Table 2), and the MCV values did not differ significantly when
the patients were divided according to the time to AVF failure
(Table 1). As inflammation and iron deficiency tend to result in
decreased MCV while vitamin B12 and B9 deficiencies are
associated with increased MCV a combination of these causes
could affect RDW while MCV would remain normal. Therefore,
we cannot fully exclude the possibility that folate or vitamin B12
deficiencies affected RDW in our study.
RDW potentially reflects an underlying inflammatory state that
leads to AVF failure. Besides RDW, WBC was an independent
prognostic marker of AVF failure, and RDW correlated positively
with CRP. These findings are consistent with previous reports of
positive correlations between RDW and the inflammatory markers
IL-6, CRP, and erythrocyte sedimentation rate [20,26]. Several of
these markers have been associated with AVF thrombosis [13,14],
but this is to our knowledge the first time RDW has been identified
as a prognostic marker for AVF failure. The relationship between
RDW and inflammation is still equivocal. Weak but significant
positive correlation with CRP, as found in our study, has also been
identified in patients with coronary disease [27]. Interestingly, the
presence of inflammatory cells in the artery/vein at the time of
surgery was not associated with an increase in RDW or monocyte
levels. One explanation may be that RDW is a very early marker
of inflammation that precedes inflammatory cell infiltration. An
elevated RDW may also reflect IL-6-mediated increases in
vascular smooth muscle cell migration and proliferation [28,29],
which potentially promote AVF failure.
Correlations between RDW and malnutrition may in part
explain the association between RDW and mortality in heart
failure [20]. Malnutrition has also been identified as a risk factor
for AVF failure [10]. In our study, no significant differences in
body mass index (BMI), cholesterol or transferrin levels were
observed between the patient groups. Albumin was lower in the
early AVF failure group but as it is affected by numerous factors
other than nutrition intake it is not a useful marker for
malnutrition [30]. Although we cannot fully exclude effects of
potential malnutrition on RDW levels it seems unlikely that this is
the main mechanistic link between high RDW and AVF failure in
our study.
Red blood cell deformability, aggregability and adherence to
the blood vessel wall endothelium can affect blood flow and
contribute to thrombosis. Increases in red blood cell aggregation
have been associated with thrombosis in for example diabetes,
coronary heart disease and hypertension [31,32]. High RDW can
Figure 3. Association between presence of inflammatory cells in the vessel wall and serum parameters. A–C, Patients in whom CD68-
positive cells were found in the radial artery or cephalic vein wall had significantly higher WBCs (p=0.002) (B), but there were no significant
differences in RDW (A) or the number of monocytes (C). D–F, No significant differences in levels of RDW (D), WBC (E), or number of monocytes (F)
were found in patients whose radial artery or cephalic vein wall contained CD45-positive cells.
doi:10.1371/journal.pone.0036482.g003
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red blood cell population, potentially associated with increased
RBC deformability, aggregability and/or adherence to the vessel
wall, contributing to thrombosis formation and subsequent AVF
failure.
Importantly, RDW seems to be a better predictor of AVF
failure then inflammatory markers such as CRP and WBC. CRP
was not a significant risk factor in multivariable analysis and the
significant correlation found between CRP and RDW was weak
(r
2=0.30). WBC, although being a significant risk factor in
multivariable analysis, was not significant in ROC curve analysis
indicating that as a laboratory test it has not the ability to
distinguish between the AVF failure and non-failure groups. RDW
may represent an integrative measure of multiple pathologic
processes, such as inflammation, nutritional defects and red blood
cell aggregation, explaining its strong association with AVF
dysfunction.
The strengths of our study are its prospective design, the
comprehensive biochemical data collected at the time of surgery,
and the availability of vessel biopsies. A potential limitation is that
patients were enrolled consecutively at a single center, so the
patient population was relatively small and heterogeneous. In
summary, we identified RDW, WBC, and the number of
monocytes as independent predictors of AVF failure. Further
studies in a larger patient cohort and involving several centers,
including further potential factors affecting RDW, are needed to
verify the prognostic value of RDW and to provide insight into the
mechanistic link between RDW and AVF failure.
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